Eli Lilly and Company (ETR:LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 683.54B |
| Revenue (ttm) | 43.51B |
| Net Income (ttm) | 10.23B |
| Shares Out | n/a |
| EPS (ttm) | 11.31 |
| PE Ratio | 66.83 |
| Forward PE | n/a |
| Dividend | 5.05 (0.67%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 645 |
| Average Volume | 3,729 |
| Open | 758.50 |
| Previous Close | 759.60 |
| Day's Range | 754.00 - 761.60 |
| 52-Week Range | 657.50 - 888.30 |
| Beta | 0.34 |
| RSI | 42.12 |
| Earnings Date | May 1, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
VIG: Index Rebalance Adds Eli Lilly To Bolster Dividend Growth In 2025
Here's How Much $1000 Invested In Eli Lilly 20 Years Ago Would Be Worth Today
Eli Lilly (NYSE: LLY) has outperformed the market over the past 20 years by 6.51% on an annualized basis producing an average annual return of 14.67%. Currently, Eli Lilly has a market capitalization...
Eli Lilly expands LillyDirect to include Alzheimer's resources
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.
Lilly adds Alzheimer's to online offerings
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose and care for patients with Alzheimer's disease, potentially boosting sales...
Checking in on the weight-loss drug space: Novo Nordisk, Eli Lilly, and others
Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds. These ETFs, focused on Eli Lilly & Co (NYSE: LLY) ...
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients
Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are neutral on FHTX stock.
'Goal is to offer more innovative medicines'
Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, Mounjaro. CEO David Ricks is optimistic about India's growth potential and ...
Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
INDIANAPOLIS , March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented a...
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal.Meanwhile, a survey shows doctors' perception of the health care system is improving.
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approach...
Eli Lilly Shares Rise Over 2% After Key Signal
LLY CLIMBS OVER 17 POINTS AT ITS HIGH Eli Lilly & Co. (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their tr...
Eli Lilly Shares Rise Over 2% After Key Signal
Eli Lilly & Co. (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
5 Stocks That Could Be The Next Nvidia
Everybody loves a great growth stock. We all know the stories of the incredible wealth delivered by fast-growing companies that keep growing for a long period of time.
The market comeback continues plus, a key catalyst is on the horizon for Eli Lilly
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
There's a price war brewing in GLP-1 weight loss drugs, and now it's going global.
Novo Nordisk's $2 billion obesity deal
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss Eli Lilly's latest obesity pill trial.
Eli Lilly Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly . Looking at options history for Eli Lilly (NYSE: LLY) we detected 9 trades. If we consider the specifics of ea...
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.
Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up front.
Sesame, America's Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly's Obesity Medicine Zepbound
New integration means streamlined ordering and paying experiences for patients, with the same direct shipping and the best self-pay price on single-dose Zepbound vials New integration means streamline...